Pulse Biosciences (NASDAQ:PLSE) Stock Rating Lowered by Wall Street Zen

Key Points

• Wall Street Zen downgraded Pulse Biosciences from “hold” to “sell,” although the broader analyst consensus remains “Moderate Buy,” with an average price target of $32.33.
• Pulse Biosciences’ shares opened at $42.41 after rising 10.9%, near its 52-week high of $45.90. The stock trades well above its 50-day and 200-day moving averages.
• The company reported a quarterly loss of $0.36 per share and revenue of $0.43 million, missing analyst expectations for a $0.29 loss and $0.53 million in revenue. Insiders own 74% of the stock, while institutional investors hold 76.95%.

Pulse Biosciences (NASDAQ:PLSE - Get Free Report) was downgraded by investment analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a note issued to investors on Saturday.

A number of other equities research analysts have also weighed in on PLSE. Canaccord Genuity Group began coverage on shares of Pulse Biosciences in a report on Thursday, June 4th. They issued a "buy" rating and a $32.00 target price on the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of Pulse Biosciences in a research note on Friday, July 17th. Finally, Oppenheimer reissued an "outperform" rating on shares of Pulse Biosciences in a report on Tuesday, July 28th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $32.33.

Pulse Biosciences Trading Up 10.9%

PLSE opened at $42.41 on Friday. The company's fifty day moving average price is $29.01 and its two-hundred day moving average price is $23.64. Pulse Biosciences has a 1-year low of $12.56 and a 1-year high of $45.90. The company has a market cap of $2.94 billion, a price-to-earnings ratio of -35.94 and a beta of 1.61.

Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.36) earnings per share for the quarter, missing analysts' consensus estimates of ($0.29) by ($0.07). The business had revenue of $0.43 million during the quarter, compared to the consensus estimate of $0.53 million. Pulse Biosciences had a negative net margin of 6,755.78% and a negative return on equity of 100.22%. As a group, equities analysts forecast that Pulse Biosciences will post -1.29 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Paul A. Laviolette bought 15,000 shares of the company's stock in a transaction on Monday, May 11th. The shares were purchased at an average price of $19.69 per share, with a total value of $295,350.00. Following the transaction, the chief executive officer directly owned 15,000 shares in the company, valued at $295,350. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Robert W. Duggan bought 660,233 shares of the company's stock in a transaction on Monday, May 11th. The shares were purchased at an average cost of $19.69 per share, for a total transaction of $12,999,987.77. Following the transaction, the director owned 48,211,433 shares in the company, valued at approximately $949,283,115.77. This represents a 1.39% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 74.00% of the stock is currently owned by insiders.

Institutional Trading of Pulse Biosciences

A number of institutional investors and hedge funds have recently modified their holdings of the business. BNP Paribas Financial Markets lifted its holdings in Pulse Biosciences by 63.6% during the second quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company's stock worth $26,000 after acquiring an additional 680 shares during the period. Tower Research Capital LLC TRC grew its stake in Pulse Biosciences by 275.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company's stock valued at $44,000 after purchasing an additional 2,156 shares during the period. Russell Investments Group Ltd. grew its stake in Pulse Biosciences by 13.8% in the 4th quarter. Russell Investments Group Ltd. now owns 5,106 shares of the company's stock valued at $70,000 after purchasing an additional 619 shares during the period. The Manufacturers Life Insurance Company purchased a new stake in shares of Pulse Biosciences during the 2nd quarter valued at $158,000. Finally, Brevan Howard Capital Management LP purchased a new stake in shares of Pulse Biosciences during the 2nd quarter valued at $215,000. 76.95% of the stock is owned by hedge funds and other institutional investors.

About Pulse Biosciences

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source